Book a meeting
DO-BO

Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in Aotearoa. 

Key insights include why New Zealand’s HTA model stands out as a global unicorn, how to navigate cultural and equity requirements in submissions, the importance of local evidence and stakeholder engagement, the impact of budget constraints and the shift toward real‑world data and outcome‑based reimbursement, and why the country may be the ideal testbed for innovations in AI, screening, and chronic care. Essential for professionals in pricing, market access, and global health policy.

Related

Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?

By

Stefan Walzer

In this brand new episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes. From streamlining evidence generation to enhancing pricing strategies and dossier creation, […]

What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?

By

Stefan Walzer

Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolving landscape of U.S. market access and reimbursement. The U.S. reimbursement landscape is changing — driven by AI, global influences with the European JCA and political programs such as […]

Will AI and Living Reviews Define the Next Era of Health Policy, Anna Forsythe?

By

Stefan Walzer

Join this episode of MAP – The Market Access Podcast as Dr. Stefan Walzer sits down with Anna Forsythe, founder of OncoScope-AI, to explore how Living Systematic Literature Reviews (Living SLRs) are redefining evidence generation in oncology and beyond – highlighting the power of real-time updates, advanced automation, and the essential role of human insight. […]